Your session is about to expire
← Back to Search
Continuous Glucose Monitoring for Gestational Diabetes (CAPO Trial)
N/A
Recruiting
Led By Audrey Merriam, MD, MS
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Women between 18-50 years old
Be between 18 and 65 years old
Must not have
Fetal growth restriction diagnosed during the current pregnancy
Abnormal diagnostic genetic testing or genetic screening for the fetus in the current pregnancy prior to randomization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum
Awards & highlights
No Placebo-Only Group
Summary
This trial will use continuous glucose monitoring to see if it lowers the rate of serious complications in women with A2 gestational diabetes.
Who is the study for?
This trial is for pregnant women aged 18-50 with a single baby and diagnosed with A2 gestational diabetes needing medication, between 24-36 weeks of pregnancy. It's not for those with pregestational diabetes, multiple babies, fetal growth issues, or certain medical conditions like lupus or chronic hypertension.
What is being tested?
The study compares the effects of continuous glucose monitoring versus routine fingerstick blood checks four times daily in managing A2 gestational diabetes during pregnancy. The goal is to see if constant monitoring can reduce complications such as high birth weight and neonatal hypoglycemia.
What are the potential side effects?
While the trial itself does not list specific side effects, continuous glucose monitoring generally has minimal risks which may include skin irritation from the sensor adhesive or discomfort at the sensor site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman aged between 18 and 50.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My current pregnancy has been diagnosed with fetal growth restriction.
Select...
My current pregnancy has shown abnormal genetic test results for the fetus.
Select...
I have been diagnosed with too much amniotic fluid.
Select...
I have a health condition such as lupus, high blood pressure, cancer, or heart disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment, through delivery by 40 weeks gestation and the immediate postpartum hospitalization up to 7 days postpartum
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Composite
Secondary study objectives
cesarean delivery for an arrest of labor disorder
hypertensive disorders of pregnancy.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Continuous Glucose MonitorExperimental Treatment1 Intervention
Monitoring of control of gestational diabetes with use of a continuous glucose monitor
Group II: Routine CareActive Control1 Intervention
Monitoring of control of gestational diabetes with routine care and use of a glucometer and fingersticks 4 times a day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Continuous Glucose Monitor
2021
Completed Early Phase 1
~860
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,920 Previous Clinical Trials
3,031,550 Total Patients Enrolled
Audrey Merriam, MD, MSPrincipal InvestigatorAssistant Professor; Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
1 Previous Clinical Trials
93 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a woman aged between 18 and 50.The baby has known health problems before birth.My current pregnancy has been diagnosed with fetal growth restriction.You missed three or more prenatal visits before being diagnosed with A2 gestational diabetes.My current pregnancy has shown abnormal genetic test results for the fetus.I was diagnosed with gestational diabetes either before 24 weeks or after 36 weeks of pregnancy.I have been diagnosed with too much amniotic fluid.I have a health condition such as lupus, high blood pressure, cancer, or heart disease.You have diabetes before becoming pregnant.I have been diagnosed with gestational diabetes needing medication in my current pregnancy between 24-36 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Continuous Glucose Monitor
- Group 2: Routine Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger